{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:54:41Z","timestamp":1795121681636,"version":"4.10.3"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41584-025-01306-w","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:32:29Z","timestamp":1760614349000},"page":"719-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-6501","authenticated-orcid":false,"given":"Marta","family":"Casal Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0637","authenticated-orcid":false,"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0938","authenticated-orcid":false,"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-6890","authenticated-orcid":false,"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-0926","authenticated-orcid":false,"given":"Joyce","family":"Kullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg M.","family":"Bajema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duvuru","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2713-2391","authenticated-orcid":false,"given":"A. Richard","family":"Kitching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-9435","authenticated-orcid":false,"given":"John H.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-1206","authenticated-orcid":false,"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-2946","authenticated-orcid":false,"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"1306_CR1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","volume":"403","author":"A Kronbichler","year":"2024","unstructured":"Kronbichler, A., Bajema, I. M., Bruchfeld, A., Mastroianni Kirsztajn, G. & Stone, J. H. Diagnosis and management of ANCA-associated vasculitis. Lancet 403, 683\u2013698 (2024).","journal-title":"Lancet"},{"key":"1306_CR2","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching, A. R. et al. ANCA-associated vasculitis. Nat. Rev. Dis. Prim. 6, 71 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1306_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000435","volume":"3","author":"C Heijl","year":"2017","unstructured":"Heijl, C., Mohammad, A. J., Westman, K. & Hoglund, P. Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis. RMD Open. 3, e000435 (2017).","journal-title":"RMD Open."},{"key":"1306_CR4","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/acr.24634","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung, S. A. et al. 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 73, 1088\u20131105 (2021).","journal-title":"Arthritis Care Res."},{"key":"1306_CR5","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1093\/ndt\/gfad090","volume":"38","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura, M. et al. Management of antineutrophil cytoplasmic antibody-associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines\/recommendations. Nephrol. Dial. Transpl. 38, 2637\u20132651 (2023).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich, B. et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann. Rheum. Dis. 83, 30\u201347 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh, M. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622\u2013631 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne, D. R. W., Merkel, P. A., Schall, T. J., Bekker, P. & Group, A. S. Avacopan for the treatment of ANCA-associated vasculitis. N. Engl. J. Med. 384, 599\u2013609 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR9","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler, M. E. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 376, 1921\u20131932 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler, M. E. et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 390, 911\u2013921 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1093\/ndt\/gfaa303","volume":"37","author":"KE Nelveg-Kristensen","year":"2020","unstructured":"Nelveg-Kristensen, K. E. et al. Increasing incidence and improved survival in ANCA-associated vasculitis \u2014 a Danish nationwide study. Nephrol. Dial. Transpl. 37, 63\u201371 (2020).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR12","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/art.39614","volume":"68","author":"RL Rhee","year":"2016","unstructured":"Rhee, R. L. et al. Trends in long-term outcomes among patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal disease. Arthritis Rheumatol. 68, 1711\u20131720 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.1780330807","volume":"33","author":"RY Leavitt","year":"1990","unstructured":"Leavitt, R. Y. et al. The American College of Rheumatology 1990 criteria for the classification of Wegener granulomatosis. Arthritis Rheum. 33, 1101\u20131107 (1990).","journal-title":"Arthritis Rheum."},{"key":"1306_CR14","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"A Masi","year":"1990","unstructured":"Masi, A. et al. The American College of Rheumatology 1990 criteria for the classification of Churg\u2013Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 33, 1094\u20131100 (1990).","journal-title":"Arthritis Rheum."},{"key":"1306_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette, J. C. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 65, 1\u201311 (2013).","journal-title":"Arthritis Rheum."},{"key":"1306_CR16","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2017-212713","volume":"77","author":"JC Robson","year":"2018","unstructured":"Robson, J. C. et al. Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. Ann. Rheum. Dis. 77, 1157\u20131164 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/rheumatology\/kead199","volume":"63","author":"A Maunz","year":"2024","unstructured":"Maunz, A. et al. Association of the AAV-PRO questionnaire with established outcome measures in AAV. Rheumatology 63, 174\u2013180 (2024).","journal-title":"Rheumatology"},{"key":"1306_CR18","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/acr.20471","volume":"63","author":"M Walsh","year":"2011","unstructured":"Walsh, M. et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 63, 1055\u20131061 (2011).","journal-title":"Arthritis Care Res."},{"key":"1306_CR19","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3899\/jrheum.110276","volume":"38","author":"PA Merkel","year":"2011","unstructured":"Merkel, P. A. et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J. Rheumatol. 38, 1480\u20131486 (2011).","journal-title":"J. Rheumatol."},{"key":"1306_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41584-025-01266-1","volume":"21","author":"G Trivioli","year":"2025","unstructured":"Trivioli, G. et al. Advances in the treatment of ANCA-associated vasculitis. Nat. Rev. Rheumatol. 21, 396\u2013413 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1306_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01794-5","volume":"16","author":"AG Sreih","year":"2021","unstructured":"Sreih, A. G. et al. Diagnostic delays in vasculitis and factors associated with time to diagnosis. Orphanet J. Rare Dis. 16, 184 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1306_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkac045","volume":"6","author":"E Dirikgil","year":"2022","unstructured":"Dirikgil, E. et al. Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients. Rheumatol. Adv. Pract. 6, rkac045 (2022).","journal-title":"Rheumatol. Adv. Pract."},{"key":"1306_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.berh.2018.10.001","volume":"32","author":"C Ponte","year":"2018","unstructured":"Ponte, C., Agueda, A. F. & Luqmani, R. A. Clinical features and structured clinical evaluation of vasculitis. Best. Pract. Res. Clin. Rheumatol. 32, 31\u201351 (2018).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1306_CR24","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/acr.22583","volume":"67","author":"R Aggarwal","year":"2015","unstructured":"Aggarwal, R. et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res. 67, 891\u2013897 (2015).","journal-title":"Arthritis Care Res."},{"key":"1306_CR25","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/art.41984","volume":"74","author":"C Dejaco","year":"2022","unstructured":"Dejaco, C. & Guillevin, L. New classification criteria for small-vessel vasculitis: is antineutrophil cytoplasmic antibody inclusion their major advance? Arthritis Rheumatol. 74, 383\u2013385 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR26","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/0003-4819-116-6-488","volume":"15","author":"GS Hoffman","year":"1992","unstructured":"Hoffman, G. S. et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 15, 488\u2013498 (1992).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/coa.12977","volume":"43","author":"A Coordes","year":"2018","unstructured":"Coordes, A. et al. Saddle nose deformity and septal perforation in granulomatosis with polyangiitis. Clin. Otolaryngol. 43, 291\u2013299 (2018).","journal-title":"Clin. Otolaryngol."},{"key":"1306_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.semarthrit.2012.08.003","volume":"42","author":"P-R Rothschild","year":"2013","unstructured":"Rothschild, P.-R. et al. Ophthalmologic manifestations of systemic necrotizing vasculitides at diagnosis: a retrospective study of 1286 patients and review of the literature. Sem. Arthritis Rheum. 42, 507\u2013514 (2013).","journal-title":"Sem. Arthritis Rheum."},{"key":"1306_CR29","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/art.11075","volume":"48","author":"JH Stone","year":"2003","unstructured":"Stone, J. H. Limited versus severe Wegener\u2019s granulomatosis: baseline data on patients in the Wegener\u2019s granulomatosis etanercept trial. Arthritis Rheum. 48, 2299\u20132309 (2003).","journal-title":"Arthritis Rheum."},{"key":"1306_CR30","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1136\/ard.2010.130203","volume":"69","author":"JU Holle","year":"2010","unstructured":"Holle, J. U. et al. Prospective long-term follow-up of patients with localised Wegener\u2019s granulomatosis: does it occur as persistent disease stage? Ann. Rheum. Dis. 69, 1934\u20131939 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR31","doi-asserted-by":"publisher","first-page":"643 e649","DOI":"10.1016\/j.amjmed.2006.08.016","volume":"120","author":"JD Finkielman","year":"2007","unstructured":"Finkielman, J. D. et al. ANCA are detectable in nearly all patients with active severe Wegener\u2019s granulomatosis. Am. J. Med. 120, 643 e649\u2013614 (2007).","journal-title":"Am. J. Med."},{"key":"1306_CR32","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/rheumatology\/kez148","volume":"58","author":"A Mahr","year":"2019","unstructured":"Mahr, A., Specks, U. & Jayne, D. Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology 58, 1707\u20131709 (2019).","journal-title":"Rheumatology"},{"key":"1306_CR33","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.ekir.2025.02.032","volume":"10","author":"L Floyd","year":"2025","unstructured":"Floyd, L. et al. Clinical presentation and outcomes of antineutrophil cytoplasmic autoantibody-negative pauci-immune glomerulonephritis. Kidney Int. Rep. 10, 1450\u20131459 (2025).","journal-title":"Kidney Int. Rep."},{"key":"1306_CR34","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1093\/rheumatology\/keae379","volume":"63","author":"M Casal Moura","year":"2024","unstructured":"Casal Moura, M. et al. Granulomatosis with polyangiitis with and without antineutrophil cytoplasmic antibodies: a case\u2013control study. Rheumatology 63, 3279\u20133288 (2024).","journal-title":"Rheumatology"},{"key":"1306_CR35","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6","volume":"42","author":"L Guillevin","year":"1999","unstructured":"Guillevin, L. et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 42, 421\u2013430 (1999).","journal-title":"Arthritis Rheum."},{"key":"1306_CR36","doi-asserted-by":"publisher","first-page":"e762","DOI":"10.1016\/S2665-9913(24)00187-5","volume":"6","author":"K Gisslander","year":"2024","unstructured":"Gisslander, K. et al. Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort. Lancet Rheumatol. 6, e762\u2013e770 (2024).","journal-title":"Lancet Rheumatol."},{"key":"1306_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102495","volume":"19","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler, A. et al. Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun. Rev. 19, 102495 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1306_CR38","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1055\/s-0038-1669914","volume":"39","author":"R Borie","year":"2018","unstructured":"Borie, R. & Crestani, B. Antineutrophil cytoplasmic antibody-associated lung fibrosis. Semin. Resp. Crit. Care Med. 39, 465\u2013470 (2018).","journal-title":"Semin. Resp. Crit. Care Med."},{"key":"1306_CR39","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2214\/AJR.18.20967","volume":"213","author":"A Suzuki","year":"2019","unstructured":"Suzuki, A. et al. Chest high-resolution CT findings of microscopic polyangiitis: a Japanese first nationwide prospective cohort study. Am. J. Roentgenol. 213, 104\u2013114 (2019).","journal-title":"Am. J. Roentgenol."},{"key":"1306_CR40","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi, G. et al. Evidence-based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat. Rev. Rheumatol. 19, 378\u2013393 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1306_CR41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond, C. et al. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65, 270\u2013281 (2013).","journal-title":"Arthritis Rheum."},{"key":"1306_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/MD.0b013e3181af35a5","volume":"88","author":"T Neumann","year":"2009","unstructured":"Neumann, T. et al. Cardiac involvement in Churg\u2013Strauss syndrome: impact of endomyocarditis. Medicine 88, 236\u2013243 (2009).","journal-title":"Medicine"},{"key":"1306_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.chest.2021.02.049","volume":"160","author":"GE Thompson","year":"2021","unstructured":"Thompson, G. E. et al. Pleuritis and pericarditis in ANCA-associated vasculitis. Chest 160, 572\u2013581 (2021).","journal-title":"Chest"},{"key":"1306_CR44","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221125979","volume":"14","author":"M Casal Moura","year":"2022","unstructured":"Casal Moura, M. et al. A glance into the future of anti-neutrophil cytoplasmic antibody-associated vasculitis. Ther. Adv. Musculoskelet. Dis. 14, 1759720X221125979 (2022).","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"1306_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3988\/jcn.2017.13.1.77","volume":"13","author":"HJ Cho","year":"2017","unstructured":"Cho, H. J. et al. Clinical characteristics and treatment response of peripheral neuropathy in the presence of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss Syndrome): experience at a single tertiary center. J. Clin. Neurol. 13, 77\u201383 (2017).","journal-title":"J. Clin. Neurol."},{"key":"1306_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/RHU.0000000000000713","volume":"24","author":"R Padoan","year":"2018","unstructured":"Padoan, R. et al. Overall disability sum score for clinical assessment of neurological involvement in eosinophilic granulomatosis with polyangiitis. J. Clin. Rheumatol. 24, 197\u2013202 (2018).","journal-title":"J. Clin. Rheumatol."},{"key":"1306_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","volume":"78","author":"L Guillevin","year":"1999","unstructured":"Guillevin, L. et al. Churg\u2013Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine 78, 26\u201337 (1999).","journal-title":"Medicine"},{"key":"1306_CR48","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico, R. A. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg\u2013Strauss syndrome. Arthritis Rheum. 52, 2926\u20132935 (2005).","journal-title":"Arthritis Rheum."},{"key":"1306_CR49","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","volume":"143","author":"R Sabl\u00e9-Fourtassou","year":"2005","unstructured":"Sabl\u00e9-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg\u2013Strauss syndrome. Ann. Intern. Med. 143, 632\u2013638 (2005).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12515-9","volume":"10","author":"PA Lyons","year":"2019","unstructured":"Lyons, P. A. et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat. Commun. 10, 5120 (2019).","journal-title":"Nat. Commun."},{"key":"1306_CR51","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3899\/jrheum.2023-0325","volume":"50","author":"E Rubenstein","year":"2023","unstructured":"Rubenstein, E. et al. Cluster analysis to explore clinical subphenotypes of eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 50, 1446\u20131453 (2023).","journal-title":"J. Rheumatol."},{"key":"1306_CR52","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1136\/annrheumdis-2016-209507","volume":"76","author":"J Damoiseaux","year":"2017","unstructured":"Damoiseaux, J. et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann. Rheum. Dis. 76, 647\u2013653 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR53","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt, X. et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat. Rev. Rheumatol. 13, 683\u2013692 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1306_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102716","volume":"20","author":"NAD Guchelaar","year":"2021","unstructured":"Guchelaar, N. A. D. et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. Autoimmun. Rev. 20, 102716 (2021).","journal-title":"Autoimmun. Rev."},{"key":"1306_CR55","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.161224","volume":"44","author":"AJ Mohammad","year":"2017","unstructured":"Mohammad, A. J. et al. Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J. Rheumatol. 44, 1458\u20131467 (2017).","journal-title":"J. Rheumatol."},{"key":"1306_CR56","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3899\/jrheum.161224","volume":"44","author":"MA Alba","year":"2017","unstructured":"Alba, M. A. et al. Pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: the influence of ANCA subtype. J. Rheumatol. 44, 1458\u20131467 (2017).","journal-title":"J. Rheumatol."},{"key":"1306_CR57","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1681\/ASN.2022020164","volume":"33","author":"M Casal Moura","year":"2022","unstructured":"Casal Moura, M., Soler, M. J., Sethi, S., Fervenza, F. C. & Specks, U. Kidney histopathology in ANCA-associated vasculitides treated with plasma exchange. J. Am. Soc. Nephrol. 33, 1223\u20131224 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1306_CR58","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/ndt\/gfu084","volume":"29","author":"LF Quintana","year":"2014","unstructured":"Quintana, L. F. et al. ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. Nephrol. Dial. Transpl. 29, 1764\u20131769 (2014).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR59","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks, U. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N. Engl. J. Med. 369, 417\u2013427 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR60","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"J Stone","year":"2010","unstructured":"Stone, J. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221\u2013232 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR61","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","volume":"75","author":"S Unizony","year":"2016","unstructured":"Unizony, S. et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann. Rheum. Dis. 75, 1166\u20131169 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR62","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/art.38389","volume":"66","author":"A Mahr","year":"2014","unstructured":"Mahr, A. et al. Prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. Arthritis Rheum. 66, 1672\u20131677 (2014).","journal-title":"Arthritis Rheum."},{"key":"1306_CR63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.semarthrit.2010.11.001","volume":"41","author":"U Arad","year":"2011","unstructured":"Arad, U. et al. Anti-neutrophil antibody associated vasculitis in systemic sclerosis. Semin. Arthritis Rheum. 41, 223\u2013229 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR64","first-page":"2064","volume":"30","author":"G Douglas","year":"2003","unstructured":"Douglas, G., Bird, K., Flume, P., Silver, R. & Bolster, M. Wegener\u2019s granulomatosis in patients with rheumatoid arthritis. J. Rheumatol. 30, 2064\u20132069 (2003).","journal-title":"J. Rheumatol."},{"key":"1306_CR65","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.04060808","volume":"4","author":"SH Nasr","year":"2009","unstructured":"Nasr, S. H. et al. Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin. J. Am. Soc. Nephrol. 4, 299\u2013308 (2009).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1306_CR66","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.semarthrit.2006.08.007","volume":"36","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals, M., Brito-Zer\u00f3n, P. & Font, J. The overlap of Sj\u00f6gren\u2019s syndrome with other systemic autoimmune diseases. Semin. Arthritis Rheum. 36, 246\u2013255 (2007).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR67","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","volume":"92","author":"SP McAdoo","year":"2017","unstructured":"McAdoo, S. P. et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 92, 693\u2013702 (2017).","journal-title":"Kidney Int."},{"key":"1306_CR68","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.nefro.2020.07.001","volume":"41","author":"C Baldallo","year":"2020","unstructured":"Baldallo, C. et al. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab. Nefrologia 41, 354\u2013355 (2020).","journal-title":"Nefrologia"},{"key":"1306_CR69","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/ndt\/gfx248","volume":"32","author":"D Jayne","year":"2017","unstructured":"Jayne, D. Vasculitis \u2014 when can biopsy be avoided? Nephrol. Dial. Transpl. 32, 1454\u20131456 (2017).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR70","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2215\/CJN.14561119","volume":"15","author":"EE van Daalen","year":"2020","unstructured":"van Daalen, E. E. et al. Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin. J. Am. Soc. Nephrol. 15, 1103\u20131111 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1306_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1681\/ASN.0000000000000274","volume":"35","author":"S Bate","year":"2024","unstructured":"Bate, S. et al. The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials. J. Am. Soc. Nephrol. 35, 335\u2013346 (2024).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1306_CR72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/00000478-199006000-00006","volume":"14","author":"KO Devaney","year":"1990","unstructured":"Devaney, K. O. et al. Interpretation of head and neck biopsies in Wegener\u2019s granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am. J. Surg. Pathol. 14, 555\u2013564 (1990).","journal-title":"Am. J. Surg. Pathol."},{"key":"1306_CR73","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1164\/ajrccm.151.2.7842215","volume":"151","author":"TE Daum","year":"1995","unstructured":"Daum, T. E. et al. Tracheobronchial involvement in Wegener\u2019s granulomatosis. Am. J. Respir. Crit. Care Med. 151, 522\u2013526 (1995).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1306_CR74","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.jocn.2011.11.034","volume":"19","author":"JB Agadi","year":"2012","unstructured":"Agadi, J. B., Raghav, G., Mahadevan, A. & Shankar, S. K. Usefulness of superficial peroneal nerve\/peroneus brevis muscle biopsy in the diagnosis of vasculitic neuropathy. J. Clin. Neurosci. 19, 1392\u20131396 (2012).","journal-title":"J. Clin. Neurosci."},{"key":"1306_CR75","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1212\/WNL.55.5.636","volume":"55","author":"MP Collins","year":"2000","unstructured":"Collins, M. P. et al. Superficial peroneal nerve\/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology 55, 636\u2013643 (2000).","journal-title":"Neurology"},{"key":"1306_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2023.152307","volume":"63","author":"T Villeneuve","year":"2023","unstructured":"Villeneuve, T., Faguer, S., Collot, S., Pugnet, G. & Pr\u00e9vot, G. HRCT imaging of pulmonary involvement in granulomatosis with polyangiitis and microscopic polyangiitis at disease onset and during follow-up. Semin. Arthritis Rheum. 63, 152307 (2023).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152726","volume":"73","author":"M Casal Moura","year":"2025","unstructured":"Casal Moura, M., Tandon, Y. K., Hartman, T. E., Ryu, J. H. & Baqir, M. Interstitial lung disease in patients with antineutrophil cytoplasmic antibody-associated vasculitis: chest CT patterns and correlation with survival. Semin. Arthritis Rheum. 73, 152726 (2025).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR78","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.39475","volume":"68","author":"M Yamagata","year":"2016","unstructured":"Yamagata, M. et al. Prevalence and responsiveness to treatment of lung abnormalities on chest computed tomography in patients with microscopic polyangiitis: a multicenter, longitudinal, retrospective study of one hundred fifty consecutive hospital-based Japanese patients. Arthritis Rheumatol. 68, 713\u2013723 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR79","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijcard.2015.06.087","volume":"199","author":"MR Hazebroek","year":"2015","unstructured":"Hazebroek, M. R. et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. Int. J. Cardiol. 199, 170\u2013179 (2015).","journal-title":"Int. J. Cardiol."},{"key":"1306_CR80","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41584-025-01250-9","volume":"21","author":"A G\u00fcl","year":"2025","unstructured":"G\u00fcl, A. et al. The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis. Nat. Rev. Rheumatol. 21, 414\u2013425 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1306_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103824","volume":"24","author":"C Triaille","year":"2025","unstructured":"Triaille, C. et al. The emerging concept of ANCA-associated vasculitis related to inborn errors of immunity. Autoimmun. Rev. 24, 103824 (2025).","journal-title":"Autoimmun. Rev."},{"key":"1306_CR82","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11739-020-02518-6","volume":"16","author":"B Fteiha","year":"2021","unstructured":"Fteiha, B., Bnaya, A., Abu Sneineh, M., Nesher, G. & Breuer, G. S. Clinical implications of ANCA positivity in a hospital setting: a tertiary center experience. Intern. Emerg. Med. 16, 429\u2013436 (2021).","journal-title":"Intern. Emerg. Med."},{"key":"1306_CR83","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1081\/JDI-100100869","volume":"22","author":"S Feriozzi","year":"2000","unstructured":"Feriozzi, S. et al. Cephotaxime-associated allergic interstitial nephritis and MPO-ANCA positive vasculitis. Ren. Fail. 22, 245\u2013251 (2000).","journal-title":"Ren. Fail."},{"key":"1306_CR84","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1093\/ndt\/14.11.2774","volume":"14","author":"N Sakai","year":"1999","unstructured":"Sakai, N. et al. Tubulointerstitial nephritis with anti-neutrophil cytoplasmic antibody following indomethacin treatment. Nephrol. Dial. Transpl. 14, 2774 (1999).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR85","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/rheumatology\/kex075","volume":"56","author":"B Seeliger","year":"2017","unstructured":"Seeliger, B. et al. Are the 1990 American College of Rheumatology vasculitis classification criteria still valid? Rheumatology 56, 1154\u20131161 (2017).","journal-title":"Rheumatology"},{"key":"1306_CR86","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/rheumatology\/keq229","volume":"50","author":"RA Watts","year":"2011","unstructured":"Watts, R. A., Suppiah, R., Merkel, P. A. & Luqmani, R. Systemic vasculitis \u2014 is it time to reclassify? Rheumatology 50, 643\u2013645 (2011).","journal-title":"Rheumatology"},{"key":"1306_CR87","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1136\/ard.2009.119032","volume":"69","author":"N Basu","year":"2010","unstructured":"Basu, N. et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann. Rheum. Dis. 69, 1744\u20131750 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR88","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/art.41986","volume":"74","author":"JC Robson","year":"2022","unstructured":"Robson, J. C. et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Arthritis Rheumatol. 74, 393\u2013399 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR89","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/art.41983","volume":"74","author":"R Suppiah","year":"2022","unstructured":"Suppiah, R. et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Arthritis Rheumatol. 74, 400\u2013406 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR90","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/art.41982","volume":"74","author":"PC Grayson","year":"2022","unstructured":"Grayson, P. C. et al. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol. 74, 386\u2013392 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR91","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/art.39860","volume":"68","author":"C Pagnoux","year":"2016","unstructured":"Pagnoux, C. & Springer, J. Editorial: classifying antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides according to ANCA type or phenotypic diagnosis: salt or pepper? Arthritis Rheumatol. 68, 2837\u20132840 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR92","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488\u2013494 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR93","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/art.33361","volume":"64","author":"M Walsh","year":"2012","unstructured":"Walsh, M. et al. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 64, 542\u2013548 (2012).","journal-title":"Arthritis Rheum."},{"key":"1306_CR94","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth, A. D. et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis. 41, 776\u2013784 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"1306_CR95","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-143-9-200511010-00005","volume":"143","author":"SL Hogan","year":"2005","unstructured":"Hogan, S. L. et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann. Intern. Med. 143, 621\u2013631 (2005).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR96","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1002\/art.23800","volume":"58","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux, C. et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 58, 2908\u20132918 (2008).","journal-title":"Arthritis Rheum."},{"key":"1306_CR97","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2012-201750","volume":"72","author":"A Mahr","year":"2013","unstructured":"Mahr, A. et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann. Rheum. Dis. 72, 1003\u20131010 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR98","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/art.39450","volume":"68","author":"X Pu\u00e9chal","year":"2016","unstructured":"Pu\u00e9chal, X. et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener\u2019s) or microscopic polyangiitis. Arthritis Rheumatol. 68, 690\u2013701 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR99","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/rheumatology\/kez016","volume":"58","author":"S Deshayes","year":"2019","unstructured":"Deshayes, S. et al. Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. Rheumatology 58, 1731\u20131739 (2019).","journal-title":"Rheumatology"},{"key":"1306_CR100","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons, P. A. et al. Genetically distinct subsets within ANCA-associated vasculitis. N. Engl. J. Med. 367, 214\u2013223 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR101","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/art.40034","volume":"69","author":"PA Merkel","year":"2017","unstructured":"Merkel, P. A. et al. Identification of functional and expression polymorphisms associated with risk for antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol. 69, 1054\u20131066 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR102","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/art.39812","volume":"68","author":"EM Miloslavsky","year":"2016","unstructured":"Miloslavsky, E. M. et al. Myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA)-positive and ANCA-negative patients with granulomatosis with polyangiitis (Wegener\u2019s): distinct patient subsets. Arthritis Rheumatol. 68, 2945\u20132952 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101845","volume":"37","author":"T Ecclestone","year":"2023","unstructured":"Ecclestone, T. & Watts, R. A. Classification and epidemiology of vasculitis: emerging concepts. Best. Pract. Res. Clin. Rheumatol. 37, 101845 (2023).","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"1306_CR104","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/rheumatology\/kead516","volume":"63","author":"J Rathmann","year":"2024","unstructured":"Rathmann, J., Segelmark, M. & Mohammad, A. J. Evaluation of the ACR\/EULAR 2022 criteria for classification of ANCA-associated vasculitis in a population-based cohort from Sweden. Rheumatology 63, 1965\u20131972 (2024).","journal-title":"Rheumatology"},{"key":"1306_CR105","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/ard.2008.097758","volume":"68","author":"PA Merkel","year":"2009","unstructured":"Merkel, P. A. et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann. Rheum. Dis. 68, 103\u2013106 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR106","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar, C. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann. Rheum. Dis. 68, 1827\u20131832 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR107","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/1529-0131(200104)44:4<912::AID-ANR148>3.0.CO;2-5","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone, J. H. et al. A disease-specific activity index for Wegener\u2019s granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis Rheum. 44, 912\u2013920 (2001).","journal-title":"Arthritis Rheum."},{"key":"1306_CR108","first-page":"671","volume":"87","author":"RA Luqmani","year":"1994","unstructured":"Luqmani, R. A. et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87, 671\u2013678 (1994).","journal-title":"QJM"},{"key":"1306_CR109","doi-asserted-by":"crossref","unstructured":"Luqmani, R. A. in Rare Diseases of the Immune System: Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (eds Albert, R. S. & Guillevin, L.) 57\u201376 (Springer Nature Switzerland, 2020).","DOI":"10.1007\/978-3-030-02239-6_5"},{"key":"1306_CR110","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1067\/mhn.2002.121022","volume":"126","author":"JF Piccirillo","year":"2002","unstructured":"Piccirillo, J. F., Merritt, M. G. Jr. & Richards, M. L. Psychometric and clinimetric validity of the 20-item Sino-Nasal Outcome Test (SNOT-20). Otolaryngol. Head. Neck Surg. 126, 41\u201347 (2002).","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"1306_CR111","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1034\/j.1399-3003.1999.14d29.x","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper, E. F., O\u2019Byrne, P. M., Guyatt, G. H., Ferrie, P. J. & King, D. R. Development and validation of a questionnaire to measure asthma control. Eur. Resp. J. 14, 902\u2013907 (1999).","journal-title":"Eur. Resp. J."},{"key":"1306_CR112","doi-asserted-by":"publisher","first-page":"i76","DOI":"10.1093\/ndt\/gfv002","volume":"30","author":"RA Luqmani","year":"2015","unstructured":"Luqmani, R. A. Disease assessment in systemic vasculitis. Nephrol. Dial. Transpl. 30, i76\u2013i82 (2015).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR113","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/art.1780400222","volume":"40","author":"AR Exley","year":"1997","unstructured":"Exley, A. R. et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 40, 2187\u20132195 (1997).","journal-title":"Arthritis Rheum."},{"key":"1306_CR114","first-page":"1357","volume":"34","author":"P Seo","year":"2007","unstructured":"Seo, P. et al. The future of damage assessment in vasculitis. J. Rheumatol. 34, 1357\u20131371 (2007).","journal-title":"J. Rheumatol."},{"key":"1306_CR115","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2015","unstructured":"Robson, J. et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology 54, 471\u2013481 (2015).","journal-title":"Rheumatology"},{"key":"1306_CR116","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1002\/art.42651","volume":"75","author":"JL Bloom","year":"2023","unstructured":"Bloom, J. L. et al. The association between age at diagnosis and disease characteristics and damage in patients with ANCA-associated vasculitis. Arthritis Rheumatol. 75, 2216\u20132227 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR117","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003956","volume":"10","author":"PJ Scherbacher","year":"2024","unstructured":"Scherbacher, P. J., Hellmich, B., Feng, Y. S. & L\u00f6ffler, C. Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis. RMD Open 10, e003956 (2024).","journal-title":"RMD Open"},{"key":"1306_CR118","doi-asserted-by":"publisher","first-page":"152010","DOI":"10.1016\/j.semarthrit.2022.152010","volume":"55","author":"JH Stone","year":"2022","unstructured":"Stone, J. H. et al. The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum. 55, 152010 (2022).","journal-title":"Semin Arthritis Rheum."},{"key":"1306_CR119","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky, E. M. et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann. Rheum. Dis. 76, 543\u2013546 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR120","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1016\/S2665-9913(23)00030-9","volume":"5","author":"NJ Patel","year":"2023","unstructured":"Patel, N. J. et al. Glucocorticoid toxicity index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 5, e130\u2013e138 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1306_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1341310","volume":"11","author":"C Desaintjean","year":"2024","unstructured":"Desaintjean, C. et al. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis. Front. Med. 11, 1341310 (2024).","journal-title":"Front. Med."},{"key":"1306_CR122","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/rheumatology\/kep103","volume":"48","author":"P Seo","year":"2009","unstructured":"Seo, P., Jayne, D., Luqmani, R. & Merkel, P. A. Assessment of damage in vasculitis: expert ratings of damage. Rheumatology 48, 823\u2013827 (2009).","journal-title":"Rheumatology"},{"key":"1306_CR123","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/acr.20276","volume":"62","author":"K Herlyn","year":"2010","unstructured":"Herlyn, K., Hellmich, B., Seo, P. & Merkel, P. A. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res. 62, 1639\u20131645 (2010).","journal-title":"Arthritis Care Res."},{"key":"1306_CR124","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/acr.20649","volume":"64","author":"G Tomasson","year":"2012","unstructured":"Tomasson, G. et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener\u2019s). Arthritis Care Res. 64, 273\u2013279 (2012).","journal-title":"Arthritis Care Res."},{"key":"1306_CR125","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1016\/S2665-9913(23)00092-9","volume":"5","author":"V Strand","year":"2023","unstructured":"Strand, V. et al. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 5, e451\u2013e460 (2023).","journal-title":"Lancet Rheumatol."},{"key":"1306_CR126","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/PROM.S144992","volume":"9","author":"JC Robson","year":"2018","unstructured":"Robson, J. C. et al. Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. Patient Relat. Outcome Meas. 9, 17\u201334 (2018).","journal-title":"Patient Relat. Outcome Meas."},{"key":"1306_CR127","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1056\/NEJM199603283341306","volume":"334","author":"MA Testa","year":"1996","unstructured":"Testa, M. A. & Simonson, D. C. Assessment of quality-of-life outcomes. N. Engl. J. Med. 334, 835\u2013840 (1996).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR128","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.outlook.2014.05.009","volume":"62","author":"M Bevans","year":"2014","unstructured":"Bevans, M., Ross, A. & Cella, D. Patient-reported outcomes measurement information system (PROMIS): efficient, standardized tools to measure self-reported health and quality of life. Nurs. Outlook 62, 339\u2013345 (2014).","journal-title":"Nurs. Outlook"},{"key":"1306_CR129","first-page":"4937","volume":"64","author":"P Delvino","year":"2025","unstructured":"Delvino, P. et al. Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study. Rheumatology 64, 4937\u20134947 (2025).","journal-title":"Rheumatology"},{"key":"1306_CR130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1112899","volume":"14","author":"L Quartuccio","year":"2023","unstructured":"Quartuccio, L. et al. Unmet needs in ANCA-associated vasculitis: physicians\u2019 and patients\u2019 perspectives. Front. Immunol. 14, 1112899 (2023).","journal-title":"Front. Immunol."},{"key":"1306_CR131","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1093\/rheumatology\/keae069","volume":"63","author":"L Floyd","year":"2024","unstructured":"Floyd, L. et al. A systematic review of patient-reported outcome measures in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology 63, 2624\u20132637 (2024).","journal-title":"Rheumatology"},{"key":"1306_CR132","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-142-8-200505030-00011","volume":"142","author":"PA Merkel","year":"2005","unstructured":"Merkel, P. A. et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: The Wegener\u2019s Clinical Occurrence of Thrombosis (WeCLOT) study. Ann. Intern. Med. 142, 620\u2013626 (2005).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR133","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/acr.20433","volume":"63","author":"R Suppiah","year":"2011","unstructured":"Suppiah, R. et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener\u2019s granulomatosis and microscopic polyangiitis. Arthritis Care Res. 63, 588\u2013596 (2011).","journal-title":"Arthritis Care Res."},{"key":"1306_CR134","doi-asserted-by":"crossref","unstructured":"Jayne, D. in Rare Diseases of the Immune System: Anti-Neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (eds Albert, R. S. & Guillevin, L.) 293\u2013311 (Springer Nature Switzerland, 2020).","DOI":"10.1007\/978-3-030-02239-6_16"},{"key":"1306_CR135","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/RHU.0000000000001030","volume":"25","author":"ME McClure","year":"2019","unstructured":"McClure, M. E. et al. Evaluation of PR3-ANCA status after rituximab for ANCA-associated vasculitis. J. Clin. Rheumatol. 25, 217\u2013223 (2019).","journal-title":"J. Clin. Rheumatol."},{"key":"1306_CR136","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003083","volume":"9","author":"B Sanchez-Alamo","year":"2023","unstructured":"Sanchez-Alamo, B. et al. Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 \u2014 treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV. RMD Open 9, e003083 (2023).","journal-title":"RMD Open"},{"key":"1306_CR137","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/acr2.11263","volume":"3","author":"I Doubelt","year":"2021","unstructured":"Doubelt, I. et al. Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol. 3, 404\u2013412 (2021).","journal-title":"ACR Open Rheumatol."},{"key":"1306_CR138","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1136\/ard.2010.131953","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror, R. et al. Treatment strategies and outcome of induction-refractory Wegener\u2019s granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann. Rheum. Dis. 69, 2125\u20132130 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR139","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin, L. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N. Engl. J. Med. 371, 1771\u20131780 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR140","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","volume":"77","author":"B Terrier","year":"2018","unstructured":"Terrier, B. et al. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Ann. Rheum. Dis. 77, 1150\u20131156 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR141","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2215\/CJN.06250519","volume":"14","author":"M McClure","year":"2019","unstructured":"McClure, M. & Jones, R. B. Treatment of relapses in ANCA-associated vasculitis. Clin. J. Am. Soc. Nephrol. 14, 967\u2013969 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1306_CR142","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s10067-019-04816-7","volume":"39","author":"R Outh","year":"2020","unstructured":"Outh, R. et al. Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study. Clin. Rheumatol. 39, 1601\u20131608 (2020).","journal-title":"Clin. Rheumatol."},{"key":"1306_CR143","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1681\/ASN.2013111233","volume":"26","author":"MJ Kemna","year":"2015","unstructured":"Kemna, M. J. et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J. Am. Soc. Nephrol. 26, 537\u2013542 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1306_CR144","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/art.39637","volume":"68","author":"LA Fussner","year":"2016","unstructured":"Fussner, L. A. et al. Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol. 68, 1700\u20131710 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR145","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.06460622","volume":"18","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura, M. et al. Maintenance of remission and risk of relapse in myeloperoxidase positive antineutrophil cytoplasmic antibody-associated vasculitis with kidney involvement. Clin. J. Am. Soc. Nephrol. 18, 47\u201359 (2023).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1306_CR146","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/ndt\/gfaa066","volume":"36","author":"LS van Dam","year":"2020","unstructured":"van Dam, L. S. et al. Proteinase-3-anti-neutrophil cytoplasmic antibodies (PR3-ANCAs) predict relapses in ANCA-associated vasculitis patients after rituximab. Nephrol. Dial. Transpl. 36, 1408\u20131417 (2020). 2021.","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR147","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard-2022-222479","volume":"82","author":"G Gamerith","year":"2023","unstructured":"Gamerith, G. et al. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann. Rheum. Dis. 82, 253\u2013261 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR148","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1681\/ASN.2021030382","volume":"32","author":"SM Moran","year":"2021","unstructured":"Moran, S. M. et al. The clinical application of urine soluble CD163 in ANCA-associated vasculitis. J. Am. Soc. Nephrol. 32, 2920\u20132932 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1306_CR149","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1016\/j.ekir.2023.08.017","volume":"8","author":"S Almaani","year":"2023","unstructured":"Almaani, S. et al. Urine and plasma complement Ba levels during disease flares in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. Rep. 8, 2421\u20132427 (2023).","journal-title":"Kidney Int. Rep."},{"key":"1306_CR150","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7326\/0003-4819-98-1-76","volume":"98","author":"AS Fauci","year":"1983","unstructured":"Fauci, A. S., Haynes, B. F., Katz, P. & Wolff, S. M. Wegener\u2019s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 98, 76\u201385 (1983).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR151","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/art.40313","volume":"69","author":"A Berti","year":"2017","unstructured":"Berti, A., Cornec, D., Crowson, C. S., Specks, U. & Matteson, E. L. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted county, Minnesota: a twenty-year US population-based study. Arthritis Rheumatol. 69, 2338\u20132350 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1306_CR152","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1046\/j.1523-1755.2003.00843.x","volume":"63","author":"JC Jennette","year":"2003","unstructured":"Jennette, J. C. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 63, 1164\u20131177 (2003).","journal-title":"Kidney Int."},{"key":"1306_CR153","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2215\/CJN.01020113","volume":"8","author":"AAE de Joode","year":"2013","unstructured":"de Joode, A. A. E. et al. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin. J. Am. Soc. Nephrol. 8, 1709\u20131717 (2013).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1306_CR154","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.semarthrit.2012.09.005","volume":"42","author":"ZY Li","year":"2013","unstructured":"Li, Z. Y., Gou, S. J., Chen, M. & Zhao, M. H. Predictors for outcomes in patients with severe ANCA-associated glomerulonephritis who were dialysis-dependent at presentation: a study of 89 cases in a single Chinese center. Semin. Arthritis Rheum. 42, 515\u2013521 (2013).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR155","doi-asserted-by":"publisher","first-page":"905","DOI":"10.2215\/CJN.08290813","volume":"9","author":"T Lee","year":"2014","unstructured":"Lee, T. et al. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin. J. Am. Soc. Nephrol. 9, 905\u2013913 (2014).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1306_CR156","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1681\/ASN.2010050477","volume":"21","author":"AE Berden","year":"2010","unstructured":"Berden, A. E. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 21, 1628\u20131636 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1306_CR157","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfab250","volume":"37","author":"M Casal Moura","year":"2021","unstructured":"Casal Moura, M., Fervenza, F. C., Specks, U. & Sethi, S. Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody associated vasculitis. Nephrol. Dial. Transpl. 37, 1710\u20131721 (2021).","journal-title":"Nephrol. Dial. Transpl."},{"key":"1306_CR158","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.kint.2018.07.020","volume":"94","author":"SR Brix","year":"2018","unstructured":"Brix, S. R. et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int. 94, 1177\u20131188 (2018).","journal-title":"Kidney Int."},{"key":"1306_CR159","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ekir.2024.01.007","volume":"9","author":"R Takeda","year":"2024","unstructured":"Takeda, R. et al. Development of a kidney prognostic score in a Japanese cohort of patients with antineutrophil cytoplasmic autoantibody vasculitis. Kidney Int. Rep. 9, 611\u2013623 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1306_CR160","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1093\/rheumatology\/keae336","volume":"64","author":"MJ Sandino-Berm\u00fadez","year":"2024","unstructured":"Sandino-Berm\u00fadez, M. J., Hern\u00e1ndez-Andrade, A., Hinojosa-Azaola, A., Mart\u00edn-Nares, E. & Mej\u00eda-Vilet, J. M. Performance of clinical and histological prognostic scores for kidney survival in ANCA-associated vasculitis. Rheumatology 64, 1981\u20131988 (2024).","journal-title":"Rheumatology"},{"key":"1306_CR161","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ekir.2024.11.019","volume":"10","author":"M Casal Moura","year":"2025","unstructured":"Casal Moura, M., Fervenza, F. C., Specks, U. & Sethi, S. \u201cNormal\u201d glomerular score correlates with outcomes in antineutrophil cytoplasmic autoantibody-associated vasculitis with glomerulonephritis. Kidney Int. Rep. 10, 596\u2013600 (2025).","journal-title":"Kidney Int. Rep."},{"key":"1306_CR162","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/ckj\/sfad009","volume":"16","author":"B Odler","year":"2023","unstructured":"Odler, B. et al. Challenges of defining renal response in ANCA-associated vasculitis: call to action? Clin. Kidney J. 16, 965\u2013975 (2023).","journal-title":"Clin. Kidney J."},{"key":"1306_CR163","doi-asserted-by":"publisher","first-page":"S617","DOI":"10.1016\/j.ekir.2024.11.1098","volume":"10","author":"L Uchida","year":"2025","unstructured":"Uchida, L. et al. WCN25-1022 long-term kidney function beyond 12 months and kidney relapse after initiation of treatment for ANCA-associated vasculitis. Kidney Int. Rep. 10, S617\u2013S618 (2025).","journal-title":"Kidney Int. Rep."},{"key":"1306_CR164","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3899\/jrheum.220851.C1","volume":"50","author":"S Moiseev","year":"2023","unstructured":"Moiseev, S. et al. Traditional and disease specific risk factors for cardiovascular events in ANCA-associated vasculitis: a multinational retrospective study. J. Rheumatol. 50, 1094 (2023).","journal-title":"J. Rheumatol."},{"key":"1306_CR165","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1093\/rheumatology\/keab071","volume":"60","author":"S Moiseev","year":"2021","unstructured":"Moiseev, S. et al. Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology 60, 4654\u20134661 (2021).","journal-title":"Rheumatology"},{"key":"1306_CR166","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1681\/ASN.2021091257","volume":"33","author":"S Steiger","year":"2022","unstructured":"Steiger, S., Rossaint, J., Zarbock, A. & Anders, H. J. Secondary immunodeficiency related to kidney disease (SIDKD)-definition, unmet need, and mechanisms. J. Am. Soc. Nephrol. 33, 259\u2013278 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1306_CR167","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/ard-2022-223401","volume":"82","author":"B Odler","year":"2023","unstructured":"Odler, B. et al. Risk factors for serious infections in ANCA-associated vasculitis. Ann. Rheum. Dis. 82, 681\u2013687 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR168","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11926-021-01002-0","volume":"23","author":"M Windpessl","year":"2021","unstructured":"Windpessl, M. et al. ANCA status or clinical phenotype \u2014 what counts more? Curr. Rheumatol. Rep. 23, 37 (2021).","journal-title":"Curr. Rheumatol. Rep."},{"key":"1306_CR169","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.3899\/jrheum.130200","volume":"40","author":"M Hilhorst","year":"2013","unstructured":"Hilhorst, M. et al. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J. Rheumatol. 40, 2042\u20132046 (2013).","journal-title":"J. Rheumatol."},{"key":"1306_CR170","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/rheumatology\/kead377","volume":"63","author":"L Nygaard","year":"2024","unstructured":"Nygaard, L. et al. Increased risk of cardiovascular disease preceding diagnosis of incident ANCA-associated vasculitis: a Danish nationwide study. Rheumatology 63, 1313\u20131321 (2024).","journal-title":"Rheumatology"},{"key":"1306_CR171","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/jep.12709","volume":"23","author":"CP Bramlage","year":"2017","unstructured":"Bramlage, C. P. et al. Management of cardiovascular risk factors in patients with ANCA-associated vasculitis. J. Eval. Clin. Pract. 23, 747\u2013754 (2017).","journal-title":"J. Eval. Clin. Pract."},{"key":"1306_CR172","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s11255-021-02857-z","volume":"53","author":"B Cetin","year":"2021","unstructured":"Cetin, B. et al. FRAX scores are increased in patients with ANCA-associated vasculitis. Int. Urol. Nephrol. 53, 2333\u20132339 (2021).","journal-title":"Int. Urol. Nephrol."},{"key":"1306_CR173","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/annrheumdis-2016-209925","volume":"76","author":"EE van Daalen","year":"2017","unstructured":"van Daalen, E. E. et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann. Rheum. Dis. 76, 1064\u20131069 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR174","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/rheumatology\/keh374","volume":"43","author":"T Pankhurst","year":"2004","unstructured":"Pankhurst, T., Savage, C. O., Gordon, C. & Harper, L. Malignancy is increased in ANCA-associated vasculitis. Rheumatology 43, 1532\u20131535 (2004).","journal-title":"Rheumatology"},{"key":"1306_CR175","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00404-022-06744-5","volume":"308","author":"AC Pecher","year":"2023","unstructured":"Pecher, A. C., Henes, M. & Henes, J. C. Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives. Arch. Gynecol. Obst. 308, 379\u2013385 (2023).","journal-title":"Arch. Gynecol. Obst."},{"key":"1306_CR176","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","volume":"84","author":"L R\u00fcegg","year":"2025","unstructured":"R\u00fcegg, L. et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann. Rheum. Dis. 84, 910\u2013926 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR177","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1681\/ASN.V95842","volume":"9","author":"KW Westman","year":"1997","unstructured":"Westman, K. W., A, B. P., Olsson, H., Ranstam, J. & Wieslander, J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener\u2019s granulomatosis or microscopic polyangiitis with renal involvement. J. Am. Soc. Neph. 9, 842\u2013852 (1997).","journal-title":"J. Am. Soc. Neph."},{"key":"1306_CR178","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1136\/ard.2010.145250","volume":"70","author":"C Heijl","year":"2011","unstructured":"Heijl, C. et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European vasculitis study group clinical trials. Ann. Rheum. Dis. 70, 1415\u20131421 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR179","doi-asserted-by":"publisher","first-page":"iii79","DOI":"10.1093\/rheumatology\/kez617","volume":"59","author":"A Kronbichler","year":"2020","unstructured":"Kronbichler, A., Leierer, J., Gauckler, P. & Shin, J. I. Comorbidities in ANCA-associated vasculitis. Rheumatology 59, iii79\u2013iii83 (2020).","journal-title":"Rheumatology"},{"key":"1306_CR180","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","volume":"76","author":"JA Tan","year":"2017","unstructured":"Tan, J. A. et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann. Rheum. Dis. 76, 1566\u20131574 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR181","doi-asserted-by":"publisher","first-page":"160","DOI":"10.7326\/M19-1564","volume":"172","author":"AW Steinberg","year":"2020","unstructured":"Steinberg, A. W., Wechsler, M. E. W. & Fern\u00e1ndez P\u00e9rez, E. R. Trends in antineutrophil cytoplasmic autoantibody-associated vasculitis-related mortality in the United States, 1999 to 2017. Ann. Intern. Med. 172, 160\u2013163 (2020).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102531","volume":"19","author":"M Scherlinger","year":"2020","unstructured":"Scherlinger, M. et al. Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmun. Rev. 19, 102531 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1306_CR183","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin, L. et al. Prognostic factors in polyarteritis nodosa and Churg\u2013Strauss syndrome. Medicine 75, 17\u201328 (1996).","journal-title":"Medicine"},{"key":"1306_CR184","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin, L. et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French vasculitis study group (FVSG) cohort. Medicine 90, 19\u201327 (2011).","journal-title":"Medicine"},{"key":"1306_CR185","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/rheumatology\/kev286","volume":"55","author":"JH Schirmer","year":"2016","unstructured":"Schirmer, J. H. et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology 55, 71\u201379 (2016).","journal-title":"Rheumatology"},{"key":"1306_CR186","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig, F. et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg\u2013Strauss, EGPA): monocentric experiences in 150 patients. Ann. Rheum. Dis. 72, 1011\u20131017 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR187","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.27763","volume":"63","author":"JU Holle","year":"2011","unstructured":"Holle, J. U. et al. Improved outcome in 445 patients with Wegener\u2019s granulomatosis in a German vasculitis center over four decades. Arthritis Rheum. 63, 257\u2013266 (2011).","journal-title":"Arthritis Rheum."},{"key":"1306_CR188","doi-asserted-by":"publisher","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","volume":"27","author":"K Matsushita","year":"2020","unstructured":"Matsushita, K. et al. Incorporating kidney disease measures into cardiovascular risk prediction: development and validation in 9 million adults from 72 datasets. eClinicalMedicine 27, 100552 (2020).","journal-title":"eClinicalMedicine"},{"key":"1306_CR189","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.kint.2023.02.029","volume":"103","author":"N Benichou","year":"2023","unstructured":"Benichou, N. et al. Proteinuria and hematuria after remission induction are associated with outcome in ANCA-associated vasculitis. Kidney Int. 103, 1144\u20131155 (2023).","journal-title":"Kidney Int."},{"key":"1306_CR190","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/j.semarthrit.2020.09.010","volume":"50","author":"S Monti","year":"2020","unstructured":"Monti, S. et al. Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. Semin. Arthritis Rheum. 50, 1314\u20131325 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR191","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.semarthrit.2021.07.001","volume":"51","author":"KA Quinn","year":"2021","unstructured":"Quinn, K. A. et al. Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: a mixed methods study from OMERACT 2020. Semin. Arthritis Rheum. 51, 1134\u20131138 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1306_CR192","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.166107","volume":"8","author":"DP Chen","year":"2023","unstructured":"Chen, D. P. et al. PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease. JCI Insight 8, e166107 (2023).","journal-title":"JCI Insight"},{"key":"1306_CR193","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002935","volume":"9","author":"M Casal Moura","year":"2023","unstructured":"Casal Moura, M. et al. Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism. RMD Open. 9, e002935 (2023).","journal-title":"RMD Open."},{"key":"1306_CR194","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJM195304302481805","volume":"248","author":"PM Zeek","year":"1953","unstructured":"Zeek, P. M. Periarteritis nodosa and other forms of necrotizing angiitis. N. Engl. J. Med. 248, 764\u2013772 (1953).","journal-title":"N. Engl. J. Med."},{"key":"1306_CR195","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0025-7125(16)31330-X","volume":"61","author":"D Alarc\u00f3n-Segovia","year":"1977","unstructured":"Alarc\u00f3n-Segovia, D. The necrotizing vasculitides. A new pathogenetic classification. Med. Clin. North. Am. 61, 241\u2013260 (1977).","journal-title":"Med. Clin. North. Am."},{"key":"1306_CR196","doi-asserted-by":"publisher","first-page":"660","DOI":"10.7326\/0003-4819-89-5-660","volume":"89","author":"AS Fauci","year":"1978","unstructured":"Fauci, A. S., Haynes, B. & Katz, P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann. Intern. Med. 89, 660\u2013676 (1978).","journal-title":"Ann. Intern. Med."},{"key":"1306_CR197","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts, R. et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis. 66, 222\u2013227 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1306_CR198","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s10157-013-0854-0","volume":"17","author":"A Craven","year":"2013","unstructured":"Craven, A. et al. ACR\/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clin. Exp. Nephrol. 17, 619\u2013621 (2013).","journal-title":"Clin. Exp. Nephrol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01306-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01306-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01306-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T01:02:21Z","timestamp":1763686941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01306-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":198,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1306"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01306-w","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"8 September 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. In the past two years, P.A.M. received funds for: consulting from AbbVie, Alpine, Amgen, ArGenx, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Commonwealth Serum Laboratories (CSL) Behring, GlaxoSmithKline, iCell, Interius, Kinevant, Kyverna, Metagenomia, Neutrolis, Novartis, NS Pharma, Q32, Quell, Regeneron, Sanofi, Sparrow, Takeda and Vistera; and for research support from AbbVie, Amgen, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eicos, Electra, GlaxoSmithKline, Neutrolis and Takeda; and stock options from Kyverna, Q32, Lifordi and Sparrow; and royalties from UpToDate. D.J. received honoraria or consulting fees from Amgen, AstraZeneca, Aurinia, Bristol-Myers Squibb, Boehringer-Ingelheim, ChemoCentryx, GlaxoSmithKline, the National Institute for Health and Care Excellence, Novartis, Otsuka, Roche\/Genentech, Takeda, UCB and CSL Vifor. M.C.C. received consulting fees from GlaxoSmithKline, AbbVie, CSL Vifor, AstraZeneca, Alexion, Boehringer-Ingelheim and Novartis; royalties from UpToDate; and was supported by the Ministerio de Ciencia, Innovaci\u00f3n y Universidades\u00a0AEI\/10.13039\/501100011033 (PID2023-152265OB-I00), FEDER-EU. N.B. received consulting or advisory board honoraria from CSL Vifor and GlaxoSmithKline, and research grant support from AstraZeneca, CSL Vifor and GlaxoSmithKline. B.H. received consulting fees from Alexion, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, InflafRx, Novartis and CSL Vifor and honoraria for lectures from AbbVie, Amgen, AstraZeneca, BMS, Boehringer, Chugai, GlaxoSmithKline, Janssen, Merck Sharp & Dohme (MSD), Pfizer, Phadia, Roche and CSL Vifor. B.T. reported consulting fees from AstraZeneca, GlaxoSmithKline, CSL Vifor, Novartis, Laboratoire Fran\u00e7ais du Fractionnement et des Biotechnologies (LFB) and Boehringer-Ingelheim. C.A.L. received research grants from Bristol-Myers Squibb, AstraZeneca, GlaxoSmithKline, NSD Pharma and non-paid consultancy royalties from Bristol-Myers Squibb, AbbVie and AstraZeneca. I.M.B. received grant support from CSL Vifor and Novartis; educational fees from Astra-Zeneca and CSL Vifor; and consulting fees from GlaxoSmithKline, Aurinia, Novartis, Amgen, Hansa and Alentis Consultancy Boards. I.M.B. also serves on the Glomerular Disease Council (CSL Vifor, Novartis), is owner of BiPath and vice-president of EUVAS. D.G. received consulting fees from Amgen, ChemoCentryx, Otsuka, Calliditas and Vera Therapeutics. F.C.F. received unrestricted research funding from Genentech\/Roche. A.R.K. received research support, contract work and consultancy fees (funds to institution) from CSL, Visterra, Alentis, Variant Bio, Patrys and Sitala; speaker fees from CSL Seqirus; royalties from UpToDate; and is the chair of the Australia and New Zealand Vasculitis Society. U.S. received consulting or advisory board honoraria from Amgen, Argenx, AstraZeneca, Boehringer-Ingelheim, ChemoCentryx, CSL Vifor and Novartis; and research grant support from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, NorthStar Medical Radioisotopes, Novartis and NS-Pharma. A.K. received honoraria or consulting fees from Amgen, AstraZeneca, Boehringer-Ingelheim, CSL Vifor, Delta4, GlaxoSmithKline, Miltenyi Biotec, Novartis, Novo Nordisk, Otsuka, Roche, Sobi and Walden Biosciences. Peer review information; and unrestricted research grants from CSL Vifor and Otsuka\u00a0received by A.K. He serves on the editorial boards of Glom Dis and Nephrol Dial Transplant. M.C.M., A.R., J.G., P.V., J.K. and J.H.S. have no competing interests to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}